Osaic Holdings’s Mineralys Therapeutics MLYS Stock Holding History

Osaic Holdings’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$31.8K	Buy	1,180 +20	+2%	+$549	﹤0.01%	5809
2026 Q1	$31.4K	Buy	1,160 +5	+0.4%	+$147	﹤0.01%	5550
2025 Q4	$41.9K	Sell	1,155 -27,369	-96%	-$1.1M	﹤0.01%	5361
2025 Q3	$448K	Buy	28,524 +27,199	+2,053%	+$588K	﹤0.01%	3513
2025 Q2	$18.1K	Buy	+1,325	New	+$19.2K	﹤0.01%	5786
2024 Q3	–	Sell	-100	Closed	-$1.17K	–	7497
2024 Q2	$1.17K	Buy	+100	New	+$1.26K	﹤0.01%	6767
2024 Q1	–	Sell	-77	Closed	-$662	–	7321
2023 Q4	$662	Buy	+77	New	+$605	﹤0.01%	6846

Other funds holding MLYS

Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Osaic Holdings's MLYS Position: Q2 2026 in Review

Osaic Holdings increased its Mineralys Therapeutics (MLYS) stake by 1.7% in Q2 2026, buying an estimated $549 and bringing the position to 1,180 shares worth $31.8K. The position accounts for ﹤0.01% of the portfolio, ranked #5809.

Osaic Holdings first reported a position in MLYS in Q4 2023 and has held it in 7 quarters since. The position peaked at $448K in Q3 2025. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

Osaic Holdings held 1,180 shares of Mineralys Therapeutics worth $31.8K as of Q2 2026.
Osaic Holdings bought 20 Mineralys Therapeutics shares in Q2 2026, an estimated $549.
Mineralys Therapeutics made up ﹤0.01% of Osaic Holdings's portfolio in Q2 2026, its #5809 holding.
Osaic Holdings first reported a position in Mineralys Therapeutics in Q4 2023 and has held it in 7 quarters since.
Osaic Holdings's Mineralys Therapeutics position peaked at $448K in Q3 2025.
224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.